|
Nov 6
|
Amneal Pharmaceuticals (NYSE:AMRX) delivers shareholders decent 83% return over 1 year, surging 11% in the last week alone
|
|
Nov 3
|
JPMorgan Overhauls Loan for Amneal Pharmaceuticals After Investor Backlash
|
|
Nov 3
|
Amneal to Participate at Upcoming Investor Conferences
|
|
Nov 1
|
Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Nov 1
|
United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
|
|
Oct 31
|
Amneal Pharmaceuticals (AMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Oct 31
|
Amneal (AMRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|
|
Sep 11
|
Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) institutional investors lost 11% over the past week but have profited from longer-term gains
|
|
Sep 6
|
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
|
|
Sep 6
|
Amneal Receives First Product Approval in China
|
|
Sep 6
|
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
|
|
Aug 25
|
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
|
|
Aug 24
|
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
|
|
Apr 28
|
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for
|